December 2001
Thorax;Dec2001 Supp, Vol. 56, piii67
Academic Journal
This article presents various studies related to treatment and investigations of lung cancer. For pneumothorax and lung biopsy the total number of operations has reached a plateau. There has been an exponential increase in the use of video-assisted thoracic surgery (VATS) matched by a similar decrease in the use of open surgery in the treatment of pneumothorax. Combination chemotherapy is the treatment of choice for the majority of patients with small cell lung cancer. Furthermore the value of combination cisplatin based chemotherapy in carefully selected patients with non small cell lung cancer has also been recognized.


Related Articles

  • Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. Minami, Seigo; Kijima, Takashi; Takahashi, Ryo; Kida, Hiroshi; Nakatani, Takeshi; Hamaguchi, Masanari; Takeuchi, Yoshiko; Nagatomo, Izumi; Yamamoto, Suguru; Tachibana, Kiyoshi; Kawase, Ichiro // BMC Cancer;2012, Vol. 12 Issue 1, p296 

    Background: Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action. Combined treatment with erlotinib and pemetrexed could potentially augment the antitumor activity of either agent...

  • Surgery.  // Current Medical Literature: Lung Cancer;2012, Vol. 6 Issue 2, p39 

    This section presents clinical reviews related to surgical intervention in treatment of lung cancer. One study suggests surgical resection for stage I and II small cell carcinoma of the lung. Details on a phase 3 study of induction treatment with concurrent chemotherapy versus chemotherapy...

  • Neoadjuvant and adjuvant therapy of non-small-cell lung cancer. Jackevičius, Algirdas; Cicėnas, Saulius; Vencevičius, Vladas; Pipirienė-Želvienė, Teresė; Mickevičius, Romualdas // Acta Medica Lituanica;2006, Vol. 13 Issue 4, p245 

    The aim of the study was to evaluate the role of neoadjuvant and adjuvant therapy of non-small-cell lung cancer (NSCLC). Most of patients (pts) were diagnosed in stage III of the disease. Follow-up results of these pts were not satisfactory: within two years after surgery many pts died from a...

  • Effects of Multiple Factors on the Prognosis of pIIIa/N2 Patients with Non-small Cell Lung Cancer. Zhenrong ZHANG; Deruo LIU; Yongqing GUO; Bin SHI; Zhiyi SONG; Yanchu TIAN // Chinese Journal of Lung Cancer;Aug2010, Vol. 13 Issue 8, p781 

    Background and objective Thoracic surgery hasn't got consensus on therapy of pIIIa/N2 non-small cell lung cancer (NSCLC). The aim of this study is to identify prognostic factors in NSCLC with N2 nodal involvement. Methods A retrospective review of disease free survival and 5-year survival for...

  • Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Debevec, Lucka; Jeric, Tina; Kovac, Viljem; Bitenc, Marko; Sok, Miha // Radiology & Oncology;2009, Vol. 43 Issue 1, p47 

    Background. The aim of the study was to establish eventual progress in routine management of lung cancer patients over a ten-year period at University Clinic for Respiratory and Allergic Diseases Golnik, Slovenia, comparing the results of analysis of 345 patients, diagnosed in 1996 (with...

  • Recent Advances in the Chemotherapy of Non-small Cell Lung Cancer. Inoue, Akira // Japanese Journal of Clinical Oncology;Jul2001, Vol. 31 Issue 7, p299 

    Focuses on the advances in the chemotherapy of non-small cell lung cancer. Choice of chemotherapeutic regimen; Evaluation of several strategies to improve the chemotherapeutic effect; Increase of the possibility of application of individualized therapy.

  • LUX-Lung 3: Afatinib extended PFS in EGFR-mutated lung adenocarcinomas.  // Hem/Onc Today;8/10/2012, Vol. 13 Issue 15, p35 

    The article discusses the findings of a phase 3 LUX-Lung 3 clinical trial which revealed that afatinib treatment significantly extended the progression-free survival (PFS) compared to standard chemotherapy treatment in patients diagnosed with advanced lung adenocarcinomas that harbor epidermal...

  • A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Sculier, J P; Paesmans, M; Lecomte, J; Van Cutsem, O; Lafitte, J J; Berghmans, T; Koumakis, G; Florin, M C; Thiriaux, J; Michel, J; Giner, V; Berchier, M C; Mommen, P; Ninane, V; Klastersky, J // British Journal of Cancer;11/15/2001, Vol. 85 Issue 10, p1444 

    The European Lung Cancer Working Party (ELCWP) designed a 3-arm phase III randomised trial to determine the role of accelerated chemotherapy in extensive-disease (ED) small-cell lung cancer (SCLC). Eligible patients were randomised between the 3 following arms: (A) Standard chemotherapy with 6...

  • Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Thatcher, N; Campos, E S De; Bell, D R; Steward, W P; Varghese, G; Morant, R; Vansteenkiste, J F; Rosso, R; Ewers, S-B; Sundal, E; Schatzmann, E; Stocker, H // British Journal of Cancer;5/1/99, Vol. 80 Issue 3/4, p396 

    Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetinαin preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion...


Read the Article


Sign out of this library

Other Topics